What is the CVR number of Preo Pharma ApS?

Preo Pharma ApS is registered with CVR / Virk under CVR 41191007.

What is the revenue of Preo Pharma ApS?

Preo Pharma ApS reported revenue of DKK -41K in 2022.

Who is the CEO of Preo Pharma ApS?

John Bondo Hansen is Management of Preo Pharma ApS, in role since 2020.

Where is Preo Pharma ApS headquartered?

Preo Pharma ApS's registered address is Langelinie Allé 7, 4. 3.

Preo Pharma ApS

APSIn liquidation

CVR 41191007Langelinie Allé 7, 4. 3Manufacture of pharmaceutical preparations · NACE 2120Est. 2020— employees

Full Risika report

Revenue 2022

DKK -41K

-114% vs 2021

EBITDA margin

100.0%

-114% vs 2021

Equity ratio

15.8%

Financial strength

Net profit 2022

DKK -54K

-129% vs 2021

EBITDA — year on yearDKK millions

Key figuresAnnual report 2022

Revenue	DKK -41K	-114%
EBITDA	DKK -41K	-114%
Net profit	DKK -54K	-129%
Total assets	DKK 344K	-9%
Equity	DKK 54K	-50%
Employees	—	—

Item	2020	2021	2022
Revenue	-161	295	-41
Staff expenses	-0	-0	-0
EBITDA	-161	295	-41
Depreciation & amort.	-0	-0	-0
EBIT	-161	295	-41
Net financials	-2	-44	-13
Profit before tax	-163	251	-54
Tax	-43	62	-0
Net profit	-120	189	-54

Item	2020	2021	2022
Total assets	132	377	344
Equity	-80	109	54
Long-term debt	0	0	0
Short-term debt	213	268	290
Total debt	213	268	290

Name	Role	Member since	Age	Other directorships
JB John Bondo Hansen Management	Management	2020	—	—

Shareholder	Type	Ownership	Votes	Since
JBHA Holding ApS	Company	100.0%	100.0%	2020

Person	Role here	Other companies
John Bondo Hansen	Management	0 companies

Preo Pharma ApS

APSIn liquidation

CVR 41191007Langelinie Allé 7, 4. 3Manufacture of pharmaceutical preparations · NACE 2120Est. 2020— employees

Full Risika report

Revenue 2022

DKK -41K

-114% vs 2021

EBITDA margin

100.0%

-114% vs 2021

Equity ratio

15.8%

Financial strength

Net profit 2022

DKK -54K

-129% vs 2021

EBITDA — year on yearDKK millions

Key figuresAnnual report 2022

Revenue	DKK -41K	-114%
EBITDA	DKK -41K	-114%
Net profit	DKK -54K	-129%
Total assets	DKK 344K	-9%
Equity	DKK 54K	-50%
Employees	—	—